论文部分内容阅读
目的探讨小剂量的米氮平与奥替溴铵联合用药与单纯使用奥替溴铵治疗腹泻型肠易激综合征的临床疗效。方法回顾性分析42例腹泻型肠易激综合征患者的临床资料。结果治疗组总有效率为95.2%,对照组总有效率为66.7%,比较差异有统计学意义(P<0.05)。治疗组治疗后HADS评分低于治疗前(P<0.05),且治疗后两组HADS评分比较差异具有统计学意义(P<0.01)。结论奥替溴铵联合米氮平能有效提高腹泻型肠易激综合征患者的生活水平,明显改善患者的生活质量,值得临床推广应用。
Objective To investigate the clinical efficacy of low dose mirtazapine and oltipranil combined with otibroramine alone in the treatment of diarrhea-predominant irritable bowel syndrome. Methods The clinical data of 42 patients with diarrhea-predominant irritable bowel syndrome were retrospectively analyzed. Results The total effective rate was 95.2% in the treatment group and 66.7% in the control group, with significant difference (P <0.05). The HADS score of the treatment group after treatment was lower than that before treatment (P <0.05), and there was significant difference between the two groups in the HADS score after treatment (P <0.01). Conclusion Otibromide combined with mirtazapine can effectively improve the quality of life of patients with diarrhea-predominant irritable bowel syndrome and significantly improve the quality of life of patients, worthy of clinical application.